{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.2","upperLimit":"4.8","value":"4.4"},{"groupId":"OG001","lowerLimit":"3.2","upperLimit":"4.8","value":"4.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"500"},{"groupId":"OG001","value":"499"}],"units":"Participants"}],"description":"Progression free survival (PFS) is the time from the date of randomization to the date of disease progression per the Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 or death. Participants alive and not meeting criteria for progression by the analysis data cut-off date were censored at their last evaluable disease assessment date.\n\nProgression is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study based on all target lesions recorded since the treatment started (the sum must also demonstrate an absolute increase of at least 5 mm), or unequivocal progression of existing non-target lesions, or any new lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Cetuximab 400 mg/m\\^2 as an initial dose, followed by 250 mg/m\\^2 intravenously (IV) every 7 days.","id":"OG000","title":"Cetuximab"},{"description":"Panitumumab 6 mg/kg IV every 14 days.","id":"OG001","title":"Panitumumab"}],"paramType":"MEDIAN","populationDescription":"Primary analysis set","reportingStatus":"POSTED","timeFrame":"From randomization until the data cut-off date of 5 February 2013. Maximum time on study was 155 weeks.","title":"Progression-free Survival","type":"SECONDARY","unitOfMeasure":"months"}